14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
KMTS vs LMRI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Kestra Medical Technologies, Ltd. (KMTS) is the stronger overall head-to-head candidate over LMRI (LMRI) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). KMTS carries a Unified Composite Score of 46.9/100 (HOLD) at $25.10 (N/M Forward P/E, -134.5% operating margin), whereas LMRI carries 32.1/100 (SELL) at $14.26 (N/M Forward P/E, N/A operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KMTS vs LMRI. Trailing 12-month operating profitability (KMTS -134.5% vs LMRI N/A) and valuation multiples (KMTS N/M vs LMRI N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ KMTS vs LMRI Key Questions & Quantitative Answers
As of Nov 20, 2026, Kestra Medical Technologies, Ltd. (KMTS) is the stronger overall head-to-head candidate over LMRI (LMRI) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). KMTS carries a Unified Composite Score of 46.9/100 (HOLD) at $25.10 (N/M Forward P/E, -134.5% operating margin), whereas LMRI carries 32.1/100 (SELL) at $14.26 (N/M Forward P/E, N/A operating margin). Technically, KMTS sits in a Neutral phase (RSI 37.6, UNCLASSIFIED options structure) and LMRI sits in a Markup phase (RSI 62.5, UNCLASSIFIED options structure).
KMTS leads the Growth & Scale pillar: KMTS posts +59.9% YoY revenue growth and +0.0% YoY earnings growth on $107M TTM revenue (53.9% gross margin, -134.5% operating margin), compared with LMRI at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, KMTS generates $107M in USD-normalized revenue versus N/A for LMRI. In operating R&D and SG&A reinvestment, KMTS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LMRI.
KMTS screens cheaper on headline valuation multiples. KMTS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.4x EV/Revenue (-109.7% FCF margin), whereas LMRI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KMTS (-73.7% ROE) versus LMRI (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, KMTS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.74β · 63% Vol realized risk). By comparison, LMRI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 85% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.